Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy_老虎社区_美港股上老虎

Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy

seekingalpha2022-02-15

Grandbrothers/iStock Editorial via Getty Images Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Rio999
·2022-02-18
淋巴癌不容易。主动暂停临床，是诚实公司的表现。调整配方后，继续实验。a good try anyway
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2211631922?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-02-15 21:56","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2211631922","market":"us","top_or_hot":-1,"title":"Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy","media":"seekingalpha","content":"<div>\n<p>Grandbrothers/iStock Editorial via Getty Images   Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (...</p>\n\n<a href=\"https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Grandbrothers/iStock Editorial via Getty Images   Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (...</p>\n\n<a href=\"https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4022","symbol_name":"陆运","start_time":0,"source_url":"https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy","article_id":"2211631922","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2211631922","pubTimestamp":1644933391,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Grandbrothers/iStock Editorial via Getty Images   Legend Biotech (NASDAQ:LEGN) is trading ~6% lower ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4022":"陆运","BK4139":"生物科技","BK4505":"高瓴资本持仓","LEGN":"传奇生物","CAR":"安飞士"},"translate_title":"在FDA临床搁置CAR-T疗法的血癌研究后，传奇生物技术公司失败","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00699":1,"CAR":1,"LEGN":1},"content_text":"Grandbrothers/iStock Editorial via Getty Images   Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (FDA) imposed a clinical hold on its Phase 1 trial for LB1901.  An autologous chimeric antigen receptor T-cell (CAR-T) therapy, LB1901, is designed to target cancerous CD4+ T-cells in the treatment of adults with relapsed or refractory T-cell lymphoma (TCL). The FDA informed its decision via e-mail on Feb. 11, and the federal agency had indicated that it would send the official clinical hold letter on Mar. 11, according to the company. Before the notification on clinical hold, the company had dosed only one patient in the study. However, after the patient experienced low CD4+ T-cell counts, Legend (LEGN) had decided to pause the trial and notified the FDA. “The patient has not experienced drug-related serious adverse events (SAEs) and is being monitored in accordance with the protocol,” the company added.  In October, Allogene (NASDAQ:ALLO) was slapped with a clinical hold by the FDA on its AlloCAR T trials. However, early this year, the company announced that the agency removed the clinical hold.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":638839155,"gmtCreate":1645167456306,"gmtModify":1645167456563,"author":{"id":"3486361727758741","authorId":"3486361727758741","name":"Rio999","avatar":"https://static.tigerbbs.com/c1e4178e32cb0fcff4b50f4dce9cc6b4","vip":1,"hat":"https://static.tigerbbs.com/64cc74234f338af2bc1439cca864443e","crmLevel":4,"crmLevelSwitch":0,"idStr":"3486361727758741","authorIdStr":"3486361727758741"},"htmlText":"淋巴癌 不容易。主动暂停临床，是诚实公司的表现。调整配方后，继续实验。a good try anyway","listText":"淋巴癌 不容易。主动暂停临床，是诚实公司的表现。调整配方后，继续实验。a good try anyway","text":"淋巴癌 不容易。主动暂停临床，是诚实公司的表现。调整配方后，继续实验。a good try anyway","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/638839155","repostId":2211631922,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}